Pinky Agarwal, MD
Neurology · Kirkland, WANPI 1245223296
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $496,306 of the $794,758 with a category attached, or 62.4%. 51 manufacturers reported payments, led by MDD US Operations, LLC at 24.4% of the total. Among neurology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,356 payments — averaging $586.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$194K
- Acadia Pharmaceuticals Inc$153K
- Kyowa Kirin, Inc.$115K
- Amneal Pharmaceuticals LLC$87K
- Adamas Pharmaceuticals, Inc.$67K
- Neurocrine Biosciences, Inc.$61K
- plus $117K from 45 others
Across 336 payments — averaging $13,787 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2M
- Biogen$813K
- Eli Lilly$747K
- Boston Scientific$315K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$240K
- Takeda Pharmaceuticals U.S.A., Inc.$161K
- plus $370K from 7 others
What the payments were for
- Consulting fees$180,73323%
- Speaking & faculty fees$496,30662%
- Travel & lodging$96,70912%
- Food & beverage$20,8133%
- Education$1970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$794,758 in reported general payments places this provider in the 95th percentile of 418 neurology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 228 | $412,441 |
| NuplazidPimavanserin Tartrate | 67 | $346,587 |
| NourianzIstradefylline | 108 | $243,477 |
| GocovriAmantadine Hcl | 55 | $238,986 |
| IngrezzaValbenazine Tosylate | 12 | $88,810 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 880 | $36,267 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 342 | $27,414 |
| Rasagiline Mesylate | 98 | $18,317 |
| CrexontCarbidopa/Levodopa | 20 | $14,963 |
| MyrbetriqMirabegron | 12 | $9,867 |
| RivastigmineRivastigmine Tartrate | 83 | $7,229 |
| Droxidopa | 15 | $5,004 |
| AmantadineAmantadine Hcl | 67 | $4,831 |
| Fludrocortisone Acetate | 85 | $2,498 |
| Rivastigmine | 17 | $2,414 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary, Crexont | $86,875 | $427,404248 claims |
| Acadia Pharmaceuticals IncNuplazid | $152,839 | $346,58767 claims |
| Kyowa Kirin, Inc.Nourianz | $114,533 | $243,477108 claims |
| MDD US Operations, LLCGocovri | $194,282 | $238,98655 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $61,385 | $88,81012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 neurology providers in Washington.
Other neurology in Kirkland
- James BowenKirkland$379K
- Jason PoonKirkland$102K
- Arash FazlKirkland$71K
- James SongKirkland$31K
- Casey NazorKirkland$10K
- Daniel BurdickKirkland$6K
- Pavle RepovicSeattle$1.1M
- Jason AldredSpokane$1M
- Stacy DonlonTacoma$613K
- Nathaniel WatsonSeattle$486K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.